Efficacy of the regimen using twice-daily β-interferon followed by the standard of care for chronic hepatitis C genotype 1b with high viral load

Hepatology Research

Volumn 42, Issue 9, 2012, Pages 864-869

  Ishikawa, Toru ^a   Kubota, Tomoyuki ^a   Abe, Hiroyuki ^a   Nagashima, Aiko ^a   Hirose, Kanae ^a   Togashi, Tadayuki ^a   Seki, Keiichi ^a   Honma, Terasu ^a   Yoshida, Toshiaki ^a   Kamimura, Tomoteru ^a  

^a Saiseikai Niigata Daini Hospital   (Japan)

Author keywords

interferon twice daily; Chronic hepatitis C; Induction therapy; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; BETA INTERFERON; HEMOGLOBIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERFERON INDUCTION; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84865122188     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2012.00995.x     Document Type: Article

References (24)

1. Lauer GM, Walker BD. Hepatitis C infection. N Engl J Med 2001; 345: 41-52.
2. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37: S95-S100.
3. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
4. McHutchison JG, Gordon SC, Schiff ER etal. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
5. Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. Jpn J Infect Dis 2002; 55: 69-77.
6. Okushin H, Morii K, Yuasa S. Efficacy of the combination therapy using twice-a-day IFN β for chronic hepatitis C. Acta Hepatol Jpn 1995; 49: 735.
7. Ikeda F, Shimomura H, Miyake M etal. Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous injection of IFN-beta. J Interferon Cytokine Res 2000; 20: 831-6.
8. Shiratori Y, Perelson AS, Weinberger L etal. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000; 33: 313-22.
9. Asahina Y, Izumi N, Uchihara M etal. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001; 34: 377-84.
10. Nakajima H, Shimomura H, Iwasaki Y etal. Anti-viral actions and viral dynamics in the early phase of three different regimens of interferon treatment for chronic hepatitis C: differences between the twice daily administration of interferon-beta treatment and the combination therapy with interferon-alpha plus ribavirin. Acta Med Okayama 2003; 57: 217-25.
11. Asahina Y, Izumi N, Uchihara M etal. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol 2003; 39: 421-7.
12. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008; 46: 78-84.
13. Kobayashi Y, Watanabe S, Konishi M etal. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993; 18: 1319-25.
14. Jensen DM, Morgan TR, Marcellin P etal. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43: 954-60.
15. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-6.
16. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther 2008; 13: 9-16.
17. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
18. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
19. Carlsson T, Reichard O, Norkrans G etal. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. J Viral Hepat 2005; 12: 473-80.
20. Suzuki F, Chayama K, Tsubota A etal. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 2001; 36: 242-7.
21. Yoshioka K, Yano M, Hirofuji H etal. Randomized controlled trial of twice-a-day administration of natural interferon β for chronic hepatitis C. Hepatol Res 2000; 18: 310-19.
22. Fujimori K, Mochida S, Matsui A, Ohno A, Fujiwara K. Possible mechanisms of elevation of serum transaminase levels during interferon-beta therapy in chronic hepatitis C patients. J Gastroenterol 2002; 37: 40-6.
23. McHutchison JG, Everson GT, Gordon SC etal. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
24. Brown NA. Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: nucleoside analogues. Expert Opin Investig Drugs 2009; 18: 709-25.